Dunhill Financial’s PTC Therapeutics PTCT Stock Holding History

Dunhill Financial’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$113	Hold	1	–	–	﹤0.01%	1364
2026 Q1	$94	Hold	1	–	–	﹤0.01%	1445
2025 Q4	$106	Buy	+1	New	+$73	﹤0.01%	1359

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Dunhill Financial's PTCT Position: Q2 2026 in Review

Dunhill Financial held its PTC Therapeutics (PTCT) position steady in Q2 2026 at 1 share worth $113. The position accounts for ﹤0.01% of the portfolio, ranked #1364.

Dunhill Financial first reported a position in PTCT in Q4 2025 and has held it in 3 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Dunhill Financial held 1 share of PTC Therapeutics worth $113 as of Q2 2026.
Dunhill Financial left its PTC Therapeutics share count unchanged in Q2 2026.
PTC Therapeutics made up ﹤0.01% of Dunhill Financial's portfolio in Q2 2026, its #1364 holding.
Dunhill Financial first reported a position in PTC Therapeutics in Q4 2025 and has held it in 3 quarters since.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.